The city of Lincoln, Nebraska, currently has 5 active clinical trials seeking participants for Healthy research studies.
Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants
Recruiting
This study will be conducted to assess the safety, tolerability, and pharmacokinetics of INCB000631 when administered orally to healthy adult participants.
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
08/15/2025
Locations: Celerion, Inc, Lincoln, Nebraska
Conditions: Healthy Participants
A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11
Recruiting
This is a randomized, double-blind, placebo controlled First in human (FIH) trial of TBD11, administered to healthy adults. The trial will be conducted in two parts. Part 1 will consist of single ascending dose (SAD) and Food effect (FE) cohorts, and Part 2 will consist of multiple ascending dose (MAD) cohorts.
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
08/01/2025
Locations: Celerion, Lincoln, Nebraska
Conditions: Healthy Adult Participants
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
Recruiting
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
07/30/2025
Locations: Velocity Clinical Research Lincoln ( Site 0004), Lincoln, Nebraska
Conditions: Healthy
First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants
Recruiting
This is a first-in-human study to evaluate safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-621 in healthy male and female adult participants.
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
03/21/2025
Locations: Celerion, Lincoln, Nebraska
Conditions: Healthy Participants Study
Relative Bioavailability of NX-5948 Tablets Vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets
Recruiting
This is a 2-cohort, fixed-sequence, 3-period, relative bioavailability, food-effect, and drug-drug interaction study. It is an open-label study evaluating the relative bioavailability of NX-5948 tablets compared to capsules, and the effect of food and an acid-reducing agent on the pharmacokinetics (PK) of NX-5948.
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
12/13/2024
Locations: Celerion, Lincoln, Nebraska
Conditions: Healthy Volunteer